Psychiatry

News

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

rofessor John Atack and Professor Simon Ward, from Cardiff University’s Medicines Discovery Institute

Welsh biotech Draig emerges with $140m in financing

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Woman injecting herself while sat at a table

MIT team develops 'years-long' drug delivery tech

Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Welsh biotech Draig emerges with $140m in financing

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

Has trial result burst BMS' Cobenfy bubble?

MIT team develops 'years-long' drug delivery tech

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Psychiatry

Editor's Picks